Gabriel Léger
Gabriel Léger
Bestätigte E-Mail-Adresse bei ucsd.edu - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia
M Mesulam, A Wicklund, N Johnson, E Rogalski, GC Léger, A Rademaker, ...
Annals of Neurology: Official Journal of the American Neurological …, 2008
4732008
Dopa decarboxylase activity of the living human brain.
A Gjedde, J Reith, S Dyve, G Leger, M Guttman, M Diksic, A Evans, ...
Proceedings of the National Academy of Sciences 88 (7), 2721-2725, 1991
1891991
6-[18F]fluoro-l-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods
H Hoshi, H Kuwabara, G Léger, P Cumming, M Guttman, A Gjedde
Journal of Cerebral Blood Flow & Metabolism 13 (1), 57-69, 1993
1131993
Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to …
H Kuwabara, P Cumming, J Reith, G Leger, M Diksic, AC Evans, ...
Journal of Cerebral Blood Flow & Metabolism 13 (1), 43-56, 1993
1131993
Pharmacological treatment of Alzheimer disease
F Massoud, GC Léger
The Canadian Journal of Psychiatry 56 (10), 579-588, 2011
1112011
Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans
P Cumming, GC Léger, H Kuwabara, A Gjedde
Journal of Cerebral Blood Flow & Metabolism 13 (4), 668-675, 1993
831993
Striatal L‐dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis
A Gjedde, GC Léger, P Cumming, Y Yasuhara, AC Evans, M Guttman, ...
Journal of neurochemistry 61 (4), 1538-1541, 1993
781993
Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
H Kuwabara, P Cumming, Y Yasuhara, GC Léger, M Guttman, M Diksic, ...
Journal of nuclear medicine: official publication, Society of Nuclear …, 1995
551995
Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa
M Guttman, G Leger, A Reches, A Evans, H Kuwabara, JM Cedarbaum, ...
Movement disorders: official journal of the Movement Disorder Society 8 (3 …, 1993
501993
Correction for partial volume effects in PET using MRI-based 3-D simulations of individual human brain metabolism
OG Rousset, Y Ma, GC Leger, AH Gjedde, AC Evans
Annals of Nuclear Medicine 7 (SUPPL. 1), S31-S32, 1993
471993
3‐O‐methyldopa administration does not alter fluorodopa transport into the brain
M Guttman, G Léger, JM Cedarbaum, A Reches, W Woodward, A Evans, ...
Annals of Neurology: Official Journal of the American Neurological …, 1992
471992
Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson …
JM Cedarbaum, G Leger, M Guttman
Clinical neuropharmacology 14 (4), 330-342, 1991
451991
Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia
GC Léger, SJ Banks
Dementia and geriatric cognitive disorders 37 (1-2), 104-112, 2014
392014
Toward a revision of criteria for the dementias
K Rockwood, RW Bouchard, R Camicioli, G Léger
Alzheimer's & Dementia 3 (4), 428-440, 2007
352007
Structural and functional MRI differences in master sommeliers: a pilot study on expertise in the brain
SJ Banks, KR Sreenivasan, DM Weintraub, D Baldock, M Noback, ...
Frontiers in Human Neuroscience 10, 414, 2016
242016
Relationship between the activities of daily living questionnaire and the montreal cognitive assessment
J Durant, GC Leger, SJ Banks, JB Miller
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 4 (1), 43-46, 2016
202016
Effect of catechol‐O‐methyltransferase inhibition on brain uptake of [18F]fluorodopa: Implications for compartmental modelling and clinical usefulness
G Léger, A Gjedde, H Kuwabara, M Guttman, P Cumming
Synapse 30 (4), 351-361, 1998
201998
Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes
JB Miller, SJ Banks, GC Léger, JL Cummings
Translational neurodegeneration 3 (1), 1-9, 2014
192014
Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.
JM Cedarbaum, G Léger, A Reches, M Guttman
Clinical neuropharmacology 13 (6), 544-552, 1990
191990
A review on primary progressive aphasia
GC Léger, N Johnson
Neuropsychiatric disease and treatment 3 (6), 745, 2007
142007
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20